Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Ian Laing

James Noble

Adaptimmune Therapeutics plc

Jaguar Gene Therapy focuses on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, according to their self-described mission.

Jaguar Gene Therapy

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Metric
Company Name	Adaptimmune Therapeutics plc	Jaguar Gene Therapy	Marker Therapeutics, Inc.
Symbol	ADAP		MRKR
MSH ID	COM:ADAPTIMMUNE	COM:JAGUARGENETHERAPY	COM:MARKERTHERAPEUTICS
Market	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology
Country	GB	US	US
Stage		Venture Round	Grant
Employee Count	449		8
Website	adaptimmune.com	jaguargenetherapy.com	markertherapeutics.com
LinkedIn			marker-therapeutics
Founders

Metric
Market Cap	293.91M		44.42M
Enterprise Value
Monthly Web Traffic		1	4.75K
Web Traffic Growth		-1.00	-0.22
Valuation
Raised Capital			2M

Metric
Revenue	60.51M	3.31M
Revenue (LTM)
Revenue (NTM)
Gross Profit	50.66M	3.31M
EBITDA	-127.91M	-14.58M
Operating Income	-137.77M	-14.58M
Net Income	-114.31M	-16.97M
EPS	-0.57	-1.93
Diluted EPS	-0.57	-1.93
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.94	0.36
Operating Profit Margin	-0.57	-1.54
EBITDA Margin	-2.11	-4.40
Net Profit Margin	-0.51	-0.88
Return on Equity	-1.17	-0.36
Return on Assets	-0.23	-0.40
Return on Capital Employed	-0.34	-0.97

COM:ADAPTIMMUNE

Adaptimmune Therapeutics plc

Last Close

0.64

22/11 21:00

Market Cap

293.91M

Beta: -

Volume Today

1.34M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.68	-4.26
P/B Ratio	1.81	2.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	19.34	15.58
EV Multiple	-1.57	-2.73

Metric
Days Sales Outstanding	4.05	2.88
Days Payables Outstanding		249.06
Days Inventory Outstanding	49.24	0.00
Operating Cycle	574.38	243.84
Cash Conversion Cycle	352.12	243.84
Asset Turnover	0.44	0.54

Metric
Operating Cash Flow	-141.43M	-16.44M
Free Cash Flow	-146.32M	-16.44M
Cash Flow to Debt	-1.47	8.84
Operating Cash Flow/Sales	-0.31	-1.93
Free Cash Flow Yield	-0.49	-0.51

Metric
Cash & Equivalents	143.99M	15.11M
Accounts Receivable	-1.30M	1.37M
Inventory		1
Goodwill
Debt to Capitalization	0.49
Debt to Assets	0.09	-0.12
Current Ratio	2.92	7.01
Quick Ratio	3.09	6.32

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.18	0.14
R&D to Revenue	1.64	1.60
SG&A to Revenue	1.01	0.79